Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA. 

CEO
Michael E. Severino
CEOMichael E. Severino
Employees
835
Employees835
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
835
Employees835

SRPT Key Statistics

Market cap
1.87B
Market cap1.87B
Price-Earnings ratio
-6.12
Price-Earnings ratio-6.12
Dividend yield
—
Dividend yield—
Average volume
3.38M
Average volume3.38M
High today
$18.25
High today$18.25
Low today
$17.16
Low today$17.16
Open price
$17.94
Open price$17.94
Volume
1.28M
Volume1.28M
52 Week high
$24.68
52 Week high$24.68
52 Week low
$14.68
52 Week low$14.68

Stock Snapshot

The current Sarepta Therapeutics(SRPT) stock price is $17.78, with a market capitalization of 1.87B. The stock trades at a price-to-earnings (P/E) ratio of -6.12.

As of 2026-10-26, Sarepta Therapeutics(SRPT) stock has fluctuated between $17.16 and $18.25. The current price stands at $17.78, placing the stock +3.6% above today's low and -2.6% off the high.

The Sarepta Therapeutics(SRPT)'s current trading volume is 1.28M, compared to an average daily volume of 3.38M.

During the past year, Sarepta Therapeutics(SRPT) stock moved between $14.68 at its lowest and $24.68 at its peak.

During the past year, Sarepta Therapeutics(SRPT) stock moved between $14.68 at its lowest and $24.68 at its peak.

SRPT News

Simply Wall St 3d
Is Sarepta Therapeutics Undervalued Following New SRP 1003 Preclinical Data?

Sarepta Therapeutics (SRPT) recently shared new preclinical data on its SRP-1003 program for myotonic dystrophy type 1, giving investors fresh information about...

Is Sarepta Therapeutics Undervalued Following New SRP 1003 Preclinical Data?

Analyst ratings

50%

of 24 ratings
Buy
29.2%
Hold
50%
Sell
20.8%

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.